CHILDREN’S PROBIOTIC RESEARCH ON NEW BACTERIA STRAINS

Following are the benefits and the research notes conducted on our powerful ingredients.

LACTOBACILLUS ACIDOPHILUS

• Binding of Ochratoxin A¹ (See Earlier comment about this toxin)
• When Lactobacillus acidophilus digests food, lactic acid and hydrogen peroxide are created. These substances kill parasites and prevent more from growing.²
• Produces natural factors that prevent the overgrowth of the yeast.³
• Threefold decrease in the incidence of vaginal yeast infections and a reduction in the frequency of Candida colonization in the vagina.⁴
• Could be used as an adjuvant treatment during anticancer chemotherapy.⁵
• Treatment of acute infectious diarrhea in children.⁶

LACTOBACILLUS REUTERI

• Effective therapy in treating infantile colic.^{7 8}
• Increases healing and decreases dehydration caused by diarrhea induced by Rotavirus. Children who receive daily doses of the probiotic while healthy are less likely to contract diarrhea and/or rotavirus.^{910 11}
• Safe for infants and children.^{12 13}
• Alleviates the occurrences of eczema.¹⁴
• Reduction of workplace sicknesses.¹⁵
• Suppresses of infections related to H. pylori¹⁶ that is linked to peptic ulcers and gastric cancer.
• Prevents and Treats Female Urogenital Tract Infections such as Gardnerella vaginalis.¹⁷
• Supports Dental Health as it is the only strain that has been shown to destroy Streptococcus mutans, which accelerates tooth decay.¹⁸
• Stops and/or reduces the overproduction of pathogens as it produces a novel broad-spectrum antibiotic substances called reuterin.¹⁹ Reuterin was found to inhibit the growth of some harmful Gram-negative and Gram-positive bacteria, along with yeasts, fungi, and protozoa, while keeping normal gut flora intact.²⁰²¹
• Relieves constipation and improves bowel movement frequency.²²
• Prophylactic L. reuteri supplementation is as effective as nystatin, in the prevention of fungal colonization and invasive candidiasis in very low birth weight infants.²³

LACTOBACILLUS RHAMNOSUS

• Summary: Resistant to gastric acid and bile, Strongly adheres to intestinal epithelial cells which may be important for competition with pathogens, stimulation of mucous production and the modulation of the host immune system. Maintains the intestinal barrier, inhibits intestinal pathogens and competes with them. Beneficial modulation of the immune system. Strongly down regulates the inflammatory responses.
• Produces antifungal metabolites.²⁴
• Bind up Aflatoxins in vitro and effective at removing aflatoxin B1²⁵ Aflatoxin is common in nuts, corn, spices, copra (dried coconut), and figs. They are known to be human carcinogens. They readily bind up macromolecules including DNA and proteins’ forming adducts which lead to cancer.²⁶
• Binding of trichothecenes (including deoxynivalenol (DON) and T-2 toxin (T-2))²⁷ T-2 toxin and DON (deoxynivalenol) toxins frequently present in our daily intake of grains have been known to induce the growth of aerobic intestinal bacteria in pigs.²⁸ DON and T-2 toxin are the only identified mycotoxins capable of altering the microbial balance of the intestine (dysbiosis), but they are frequently present in our daily intake of grains.²⁹
  • DON effects on the body³⁰:
    • Enhances T-2 cytokine expression in mice
    • Increase expression IL-4, 6,10 and T-2 Toxins.
    • Suppresses TH1 immune and IFN-gamma production in murine (mice) models.
    • Potentiates action of IL-1, TNF alpha, and LPS.
    • Stimulates production of Peyer’s patches (lymph tissue in gut) via MAP kinases (excessive growth can be pathogenic).
    • Proinflammatory cytokine production.
    • COX-2 Expression.
    • Diarrhea is often associated with DON and this mycotoxin should be considered in the differential of anyone presenting with IBD or diarrhea of unexplained origin.³¹
• Binding of Zearalenone and its derivative a-zearalenol³² This is a mycotoxin, is a potent estrogenic metabolite produced by some Fusarium and Gibberella species, Zearalenone is the primary toxin, causing infertility, abortion or other breeding problems, especially in swine. Zearalenone is heat-stable and is found worldwide in a number of cereal crops, such as maize, barley, oats, wheat, rice, and sorghum.³³
• Binding of Ochratoxin A³⁴ (See Earlier comment about this toxin).
• Treatment of acute infectious diarrhea in children.³⁵
• Adjuvant therapy for H. pylori eradication.³⁶
• Alleviates some symptoms of irritable bowel syndrome.³⁷

BIFIDOBACTERIUM BIFIDUM

• Summary: predominant anaerobic flora in the intestinal tract of breast-fed newborns. Binds to human intestinal mucus. Competes with pathogens for adhesion to the epithelial cells. Increases mucin expression in the jejunum and ileum. Beneficial modulation of the immune system. Strongly down regulates inflammatory responses
  Bifidobacteria have also been seen to help in cancer prevention and therapy.³⁸
• Alleviate Chronic constipation.³⁹
• Alleviates allergy symptoms.⁴⁰⁴¹
• Resides in the colon where it enhances nutrient absorption; particularly B-vitamin absorption. Bifidobacterium bifidum also optimizes digestion, maintains a healthy balance in the colon, and prevents histamine production. Histamine is the chemical that triggers allergic reactions.

BIFIDOBACTERIUM BREVE

• Fights Cancerous Tumors.
• Helps with antibiotic associated diarrhea, allergies, gas and irritable bowel syndrome.
• Supports healthy immune system.
• Appears to inhibit E. coli.
• Constipation relief in children.
• Strong anti-inflammatory properties.
• Supports better weight gain in infants.
• Effective against influenza virus infection, it can be used as a probiotic for protection against infection.
• May be beneficial in the chronic treatment of asthma.
• May protect immune system from highly infectious agents such as Salmonella typhi.
• medical studies link a shortage of B. Breve to ailments such as antibiotic-associated diarrhea, allergies, gas, and irritable bowel syndrome.
• Restores Bifidobacterium to normal levels.⁴²
• Supports a healthy immune system.⁴³
• Promotes respiratory health.⁴⁴⁴⁵
• Supports skin health.⁴⁶⁴⁷
• Appears to inhibit E. coli.
• B. breve has been found to make up a majority of the colon’s bacteria of breastfed babies.
• Support a possible role for B. breve in mediating anti-inflammatory and antiallergic reactions by modulating the expression of inflammatory molecules during the newborn period and by regulating the expression of co-stimulatory molecules during the weaning period.⁴⁸
• Effective in increasing stool frequency in children with functional constipation. Furthermore it has a positive effect with respect to stool consistency, decreasing the number of faecal incontinence episodes and in diminishing abdominal pain.⁴⁹
• Findings show that Bifidobacterium breve have strong anti-inflammatory properties that are comparable to budesonide (Steroid Therapy) and therefore may be beneficial in the treatment of chronic asthma.⁵⁰
• Colonize the immature bowel very effectively and is associated with fewer abnormal abdominal signs and better weight gain in VLBW infants.⁵¹
• Suitable probiotic strain for routine use in preterm neonates.⁵²
• Treatment with this probiotic may enhance the mucosal barrier and protect the host from infection and inflammation. This could be of benefit for IBD patients, their first-degree relatives, and patients undergoing chemotherapy or radiation therapy to prevent intestinal injury.⁵³
• B. breve prevents intestinal inflammation through the induction of intestinal IL-10-producing Tr1 cells.⁵⁴
• Secreted components exert anti-inflammatory effects in the gastrointestinal tract.⁵⁵ This supernatant may protect immune system from highly infectious agents such as Salmonella typhi and can down-regulate pro-inflammatory pathways.⁵⁶
• Exhibits a protective effect against influenza virus infection, it can be used as a probiotic for protection against infection.⁵⁷
• B. breve could favor the recruitment of innate immune cells to the mucosa reinforcing, as well as the physical barrier of the intestinal epithelium.⁵⁸

BIFIDOBACTERIUM INFANTIS

Improve Digestive Conditions

• Treatment of acute infectious diarrhea in children.⁵⁹
• Alleviates some symptoms of irritable bowel syndrome.⁶⁰
• Antibacterial effect against pathogens such as Clostridia, Shigella, and Salmonella which may show benefit in the protection against gastroenteritis.⁶¹

BIFIDOBACTERIUM LACTIS

Fight Cancerous Tumors

• Increase tumoricidal activity.⁶²

Improve Digestive Conditions

• Improve general digestive comfort.
• Decrease intestinal permeability⁶³
• Decrease gluten’s toxic effects to intestinal lining.⁶⁴⁶⁵
• Decrease lactose intolerance.
• Normalize bowel movements.⁶⁶
• Decrease IBS symptoms.⁶⁷
• Decrease constipation.⁶⁸
• Treat acute diarrhea.⁶⁹
• Prevention of antibiotic-associated diarrhea in infants.⁷⁰

Oral Health from B. Lactis

• Decrease cavity causing bacteria in mouth (Salivary mutans).⁷¹
• Fight dental caries.

Enhance Immunity

• Reduce frequency & severity of respiratory diseases.⁷²
• Increase vaccination immune response.⁷³
• Increase immunity among the elderly.⁷⁴
• Inhibit H. pylori (can cause ulcers).
• Increase T-cell activity as needed.
• Strengthen the immune system.⁷⁵
• Reduce colds and flu.

Reduce Allergies and Inflammation

• Decrease atopic dermatitis symptoms and sensitivity.
• Decrease inflammatory responses.⁷⁶

Diabetes Management

• Increase blood glucose control.

Improve Cholesterol

• Decrease total cholesterol.
• Increase HDL-cholesterol.

BIDIFOBACTERIUM LONGUM

• Summary: Gut Health, Gut Inflammation, And Immune Health. Proven Health Benefits, Safe, and Resistant to gastric acid and bile.⁷⁷ B. Longum binds to human intestinal mucus.⁷⁸ According to scientists, Bifidobacterium longum is among the first colonizers of the sterile digestive tract of newborns and predominates in breast-fed infants.⁷⁹ Inhibits intestinal pathogen development. Used in Clinical Trials on the Prevention of Relapse in Ulcerative Colitis Patients. Beneficial modulation of the immune system. Strongly down regulates the inflammatory responses.
• Produces important B vitamins thus lowering homocysteine levels in the blood.⁸⁰
• Inhibit toxic bacteria and ammonia production.⁸¹
• Reestablish healthy vaginal flora.⁸²
• Hepatic total lipid content is closely associated with gut probiotic flora. Oral supplementation with probiotics attenuates hepatic fat accumulation without improving body weight and intestinal permeability.
• Ifidobacterium longum has a superior ability to attenuate liver fat accumulation compared to Lactobacillus acidophilus.⁸³

RESEARCH FOOTNOTES

1. Piotrowska, M., & Zakowska, Z. (2005). The limitation of ochratoxin A by lactic acid bacteria strains. Polish Journal of Microbiology, 54, 279–286.
2. “Lactobacillus Acidophilus.” University of Maryland Medical Center. http://www.umm.edu/altmed/articles/lactobacillus-acidophilus-000310.htm.
3. Fitzsimmons N, Berry DR. Inhibition of Candida albicans by Lactobacillus acidophilus: evidence for the involvement of a peroxidase system. Microbios 1994;80:125–33.
4. Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992;116:353–7.
5. Millette, M. et al. 2010. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutrition and Cancer. 62(3):371-8.
6. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004;(2):CD003048.
7. Savino F, Pelle E, Palumeri E, Oggero R, Miniero R: Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007, 119(1): 124-130.
8. Sung V.Probiotic interventions in infantile colic. Curr Opin Clin Nutr Metab Care. 2015 May;18(3):307-11.
9. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T: Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. Journal of Pediatric Gastroenterological Nutrition 1997, 24(4): 399-404.
10. Shornikova AV, Casas IA, Mykkanen H, Salo E, Vesikari T: Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatric Infectious Disease Journal 1997, 16(12): 1103-1107.
11. Dinleyici EC, Dalgic N, Guven S, Metin O, Yasa O, Kurugol Z, Turel O, Tanir G, Yazar AS, Arica V, Sancar M, Karbuz A, Eren M, Ozen M, Kara A, Vandenplas Y. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr (Rio J). 2015 May 15.
12. Dinleyici EC, Dalgic N, Guven S, Metin O, Yasa O, Kurugol Z, Turel O, Tanir G, Yazar AS, Arica V, Sancar M, Karbuz A, Eren M, Ozen M, Kara A, Vandenplas Y. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr (Rio J). 2015 May 15.
13. Cekola PL, Czerkies LA, Storm HM, Wang MH, Roberts J, Saavedra JM.
    Growth and Tolerance of Term Infants Fed Formula With Probiotic Lactobacillus reuteri.Clin Pediatr (Phila). 2015 Mar 10.
14. Abrahamsson TR, Jakobsson T, Bottcher MF, Fredrikson M, Jenmalm MC, Bjorksten B, Oldaeus G: Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial.Journal of Allergy and Clinical Immunology 2007, 119(5): 1174-1180.
15. Tubelius P, Stan V, Zachrisson A: Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomized, double blind, placebo-controlled study. Environmental Health 2005, 4:25.
16. Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, Takahashi S: Lactobacillus reuteri tablets suppress Helicobacter pylori infection – a double-blind randomized placebo-controlled cross-over clinical study.Kansenshogaku Zasshi 2007, 81(4): 387-393.
17. Reid G, et al. Oral used of Lactobacillus rhamnosus GR-1 and L fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunology & Medical Microbiology, Volume 35, issue 2, pages 131-134, March 2003.
18. Nikawa H, Makihira S, Fukushima H, Nishimura H, Ozaki Y, Ishida K, Darmawan S, Hamada T, Hara K, Matsumoto A, Takemoto T, Objectivei R. Lactobacillus reuteri in fermented bovine milk decreases the oral carriage of mutans streptococci. (2004) International Journal of Food Microbiology 95: 219-223.
19. Talarico TL, Casas IA, Chung TC, Dobrogosz WJ (1988). “Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri”. Antimicrobial Agents and Chemotherapy 32 (12): 1854–8.
20. Talarico TL, Dobrogosz WJ (May 1989). “Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri”. Antimicrob. Agents Chemother. 33 (5): 674–9.
21. Casas, Ivan A., Dobrogosz, Walter J. (December 1, 2000). “Validation of the Probiotic Concept: Lactobacillus reuteri Confers Broad-spectrum Protection against Disease in Humans and Animals”. Microbial Ecology in Health and Disease 12 (4).
22. Ojetti V, Ianiro G, Tortora A, D’Angelo G, Di Rienzo TA, Bibbò S, Migneco A, Gasbarrini A.
    The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointestin Liver Dis. 2014 Dec;23(4):387-91.
23. Oncel MY, Arayici S, Sari FN, Simsek GK, Yurttutan S, Erdeve O, Saygan S, Uras N, Oguz SS, Dilmen U.Comparison of Lactobacillus reuteri and nystatin prophylaxis on Candida colonization and infection in very low birth weight infants. J Matern Fetal Neonatal Med. 2014 Oct 9:1-5.
24. Dalie D.K.D., Deschamps A.M., Richard-Forget F. Lactic acid bacteria – Potential for control of mould growth and mycotoxins: A review (2010) Food Control, 21 (4) , pp. 370-380.
25. Haskard, C., El-Nezami, G. S., Kankaanpaa, P. E., Salminen, S., & Ahokas, J.T. (1998) Sequestration of Aflatoxin B1 by probiotic strains: Binding capacity and localization. Revue de Medecine Veterinaire, 149,571
26. Advancing Medicine with Food and Nutrients 2nd Ed. Pg 839-40
27. El-Nezami, H. S., Chrevatidis, A., Auriola, S., Salminen, S., & Mykkänen, H. (2002c). Removal of common Fusarium toxins in vitro by strains of Lactobacillus and Propionibacterium. Food Additives and Contaminants, 19, 680–686.
28. International Journal of Molecular Science, 2009. 10(1): p. 1-17
29. Advancing Medicine with Food and Nutrients 2nd Ed. Pg 830
30. Medical Mycology 2010. 56: p. 282-294, Toxicology and Applied Pharmacology, 2008. 228(1): p. 84-92
31. Advancing Medicine with Food and Nutrients 2nd Ed. Pg 834
32. El-Nezami, H. S., Polychronaki, N., Salminen, S., & Mykkänen, H. (2002a). Binding rather metabolism may explain the interaction of two food-grade Lactobacillus strains with zearalenone and its derivative a-zearalenol. Applied and Environmental Microbiology, 68, 3545–3549.
33. Kuiper-Goodman, T.; Scott, P. M.; Watanabe, H. (1987). “Risk Assessment of the Mycotoxin Zearalenone”. Regulatory Toxicology and Pharmacology 7 (3): 253–306.
34. Piotrowska, M., & Zakowska, Z. (2005). The limitation of ochratoxin A by lactic acid bacteria strains. Polish Journal of Microbiology, 54, 279–286.
35. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004;(2):CD003048.
36. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155–68.
37. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007; 25: 177–84.
38. Yoshinori HAMAJI, Minoru FUJIMORI, Takayuki SASAKI, Hitomi MATSUHASHI, Keiichi MATSUI-SEKI, Yuko SHIMATANI-SHIBATA, Yasunobu KANO, Jun AMANO and Shun’ichiro TANIGUCHI, “Strong Enhancement of Recombinant Cytosine Deaminase Activity in Bifidobacterium longum for Tumor-Targeting Enzyme/Prodrug Therapy”, Biosci. Biotechnol. Biochem., Vol. 71, 874-883 (2007).
39. Amenta, Michele et al. “Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight)”. Acta Biomed. Published December 2006.
40. Xiao,JZ et al. “Clinical Efficacy of Probiotic Bifidobacterium longum for the Treatment of Symptoms of Japanese Cedar Pollen Allergy in Subjects Evaluated in an Environmental Exposure Unit”. Allergology International. Published March 2007.
41. Ohno Hiroshi, Tsunemine Satoru, Isa Yasuhiro, Shimakawa Masaki, Yamamuru Hideki. Oral Administration Bifidobacterium bifidum G9-1 Suppresses Total and Antigen SpecificImmunoglobulin E Production in Mice. Biological and Pharmaceutical Bulletin 28(8)pp.1462-1466 20050801
42. Li Y, et al. Pediatr Int. 2004 Oct;46(5):509-15.
43. Ezaki S, et al. Allergol Int. 2012 Mar;61(1):107-13.
44. van der Aa LB, et al. Allergy. 2011 Feb;66(2):170-7.
45. van de Pol MA, et al. Allergy. 2011 Jan;66(1):39-47.
46. Van der Aa LB, et al. Clin Exp Allergy. 2010 May;40(5):795-804.
47. Taniuchi S, et al. Journal of Applied Research. 2005;5(2):387-96.
48. Ohtsuka Y, Ikegami T, Izumi H, Namura M, Ikeda T, et al. (2012) Effects of Bifidobacterium breve on inflammatory gene expression in neonatal and weaning rat intestine. Pediatr Res 71: 46–53. doi: 10.1038/pr.2011.11
49. Tabbers M, de Milliano I, Roseboom M, Benninga M. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutrition Journal. 2011;10:19. doi:10.1186/1475-2891-10-19.
50. Sagar S, Morgan ME, Chen S, et al. Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma. Respiratory Research. 2014;15(1):46. doi:10.1186/1465-9921-15-46.
51. Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura M. Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial. Archives of Disease in Childhood Fetal and Neonatal Edition. 1997;76(2):F101-F107.
52. Patole S, Keil AD, Chang A, et al. Effect of Bifidobacterium breve M-16V Supplementation on Fecal Bifidobacteria in Preterm Neonates – A Randomised Double Blind Placebo Controlled Trial. Cameron DW, ed. PLoS ONE. 2014;9(3):e89511. doi:10.1371/journal.pone.0089511.
53. Natividad JMM, Hayes CL, Motta J-P, et al. Differential Induction of Antimicrobial REGIII by the Intestinal Microbiota and Bifidobacterium breve NCC2950. Applied and Environmental Microbiology. 2013;79(24):7745-7754. doi:10.1128/AEM.02470-13.
54. Jeon SG, Kayama H, Ueda Y, et al. Probiotic Bifidobacterium breve Induces IL-10-Producing Tr1 Cells in the Colon. Goodman AL, ed. PLoS Pathogens. 2012;8(5):e1002714. doi:10.1371/journal.ppat.1002714.
55. Adams CA (2010) The probiotic paradox: live and dead cells are biological response modifiers. Nutr. Res. Rev. 23: 37–46 [PubMed]
56. Bermudez-Brito M, Muñoz-Quezada S, Gomez-Llorente C, et al. Cell-Free Culture Supernatant of Bifidobacterium breve CNCM I-4035 Decreases Pro-Inflammatory Cytokines in Human Dendritic Cells Challenged with Salmonella typhi through TLR Activation. Mattei F, ed. PLoS ONE. 2013;8(3):e59370. doi:10.1371/journal.pone.0059370.
57. Yasui H, Kiyoshima J, Hori T, Shida K. Protection against Influenza Virus Infection of Mice Fed Bifidobacterium breve YIT4064. Clinical and Diagnostic Laboratory Immunology. 1999;6(2):186-192.
58. Sánchez B, González-Rodríguez I, Arboleya S, et al. The Effects of Bifidobacterium breve on Immune Mediators and Proteome of HT29 Cells Monolayers. BioMed Research International. 2015;2015:479140. doi:10.1155/2015/479140.
59. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004;(2):CD003048.
60. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541–51.
61. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol. 1994 Oct;77(4):412-20.
62. Matsumoto M, Benno Y. Consumption of Bifidobacterium lactis LKM512 yogurt reduces gut mutagenicity by increasing gut polyamine contents in healthy adult subjects. Mutat Res. 2004 Dec 21;568(2):147-53.
63. Bergmann KR, Liu SXL, Tian R, et al. Bifidobacteria Stabilize Claudins at Tight Junctions and Prevent Intestinal Barrier Dysfunction in Mouse Necrotizing Enterocolitis. The American Journal of Pathology. 2013;182(5):1595-1606. doi:10.1016/j.ajpath.2013.01.013.
64. Cinova J, De Palma G, Stepankova R, et al. Role of Intestinal Bacteria in Gliadin-Induced Changes in Intestinal Mucosa: Study in Germ-Free Rats. Leulier F, ed. PLoS ONE. 2011;6(1):e16169. doi:10.1371/journal.pone.0016169.
65. Cinova J, De Palma G, Stepankova R, et al. Role of Intestinal Bacteria in Gliadin-Induced Changes in Intestinal Mucosa: Study in Germ-Free Rats. Leulier F, ed. PLoS ONE. 2011;6(1):e16169. doi:10.1371/journal.pone.0016169.
66. Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scandinavian Journal of Gastroenterology. 2011;46(9):1057-1064. doi:10.3109/00365521.2011.584895.
67. Whorwell PJ. Do Probiotics Improve Symptoms in Patients with Irritable Bowel Syndrome? Therapeutic Advances in Gastroenterology. 2009;2(4 Suppl):37-44. doi:10.1177/1756283X09335637.
68. Tabbers MM, Chmielewska A, Roseboom MG, et al. Effect of the consumption of a fermented dairy product containing Bifidobacterium lactis DN-173 010 on constipation in childhood: a multicentre randomised controlled trial (NTRTC: 1571). BMC Pediatrics. 2009;9:22. doi:10.1186/1471-2431-9-22.
69. Chouraqui et al. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):288-92.
70. Corrêa et al. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005 May-Jun;39(5):385-9.
71. Caglar et al. Short-term effect of icecream containing Bifidobacterium lactis Bb-12 on the number of salivary mutans streptococci and lactobacilli. Acta Odontol Scand. 2008 Jun;66(3):154-8.
72. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics. 2005;115:5. [PubMed]
73. Prescott et al. Probiotic Study Group. Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection. Clin Exp Allergy. 2008 Oct;38(10):1606-14.
74. Chiang et al.Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr. 2000 Nov;54(11):849-55.
75. Klein et al. Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults. Eur J Clin Nutr. 2008 May;62(5):584-93.
76. Matsumoto M, Benno Y. Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512. Biosci Biotechnol Biochem. 2006 Jun;70(6):1287-92.
77. Sánchez B, Champomier-Vergès MC, Collado Mdel C, Anglade P, Baraige F, Sanz Y, de los Reyes-Gavilán CG, Margolles A, Zagorec M. Low-pH adaptation and the acid tolerance response of Bifidobacterium longum biotype longum. Appl Environ Microbiol. 2007 Oct;73(20):6450-9.
78. He F, Ouwehan AC, Hashimoto H, Isolauri E, Benno Y, Salminen S. Adhesion of Bifidobacterium spp. to human intestinal mucus. Microbiol Immunol. 2001;45(3):259-62.
79. Biasucci G, Rubini M, Riboni S, Morelli L, Bessi E, Retetangos C. Mode of delivery affects the bacterial community in the newborn gut. Early Hum Dev. 2010 Jul;86 Suppl 1:13-5.
80. Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr. 2005 Jan;15(1):77-80.
81. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr. 2001 Feb;73(2 Suppl):465S-470S.
82. Korshunov VM, Gudieva ZA, Efimov BA, Pikina AP, Smeianov VV, Reid G, Korshunova OV, Tiutiunnik VL, Stepin II. [The vaginal Bifidobacterium flora in women of reproductive age]. Zh Mikrobiol Epidemiol Immunobiol. 1999 Jul-Aug;(4):74-8.
83. Xu R, Wan Y, Fang Q, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. Journal of Clinical Biochemistry and Nutrition. 2012;50(1):72-77. doi:10.3164/jcbn.11-38.